IDP-023 + interleukin-2

IDP-023 + interleukin-2 is an investigational combination therapy consisting of **IDP-023**, an off-the-shelf, allogeneic cell product made of a rare subset of natural killer cells called **g-NK cells** (gamma NK cells, characterized by lacking FcεR1γ and arising from epigenetic modulation post-exposure to cytomegalovirus) and **interleukin-2** (IL-2, a cytokine that supports the growth and activity of NK cells and other immune cells)[1][3][7]. IDP-023 is developed to kill harmful cells expressing human leukocyte antigen E (HLA-E), including certain autoreactive T and B cells and cancer cells, with a particular enhancement of immune activity and cytotoxicity. Preclinical models show that g-NK cells like IDP-023 have more robust cytokine production and tumor cell killing compared to conventional NK cells, especially when combined with antibody therapies or IL-2[1][2][5][7]. This drug combination is being evaluated for relapsed/refractory hematologic malignancies (multiple myeloma, non-Hodgkin lymphoma) and progressive forms of multiple sclerosis, usually in combination with antibody therapies like rituximab, daratumumab, or ocrelizumab[1][3][5][7].

Other names

g-NK cell therapy + IL-2